Sparton Corporation’s wholly-owned subsidiary, Sparton Medical Systems, Inc., is the contract design and manufacturing partner to Neuronetics, for the Company’s NeuroStar® TMS Therapy System. NeuroStar® was just named a Medical Design Excellence Award winner and will be honored at a ceremony at the Medical Design & Manufacturing (MD&M) East Conference and Exposition, June 10, 2009, at New York City’s Jacob K. Javits Convention Center.
The award recipients will be announced at this ceremony while Sparton Medical Systems and other named suppliers will be in attendance along with Neuronetics. The Medical Design Excellence Award is organized and presented by Canon Communications LLC (Los Angeles) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products.
A comprehensive review of entries was performed by an impartial panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine and diagnostics.
This award winning product, The NeuroStar® TMS Therapy System, is the first and only TMS (Transcranial Magnetic Stimulation) device cleared by the FDA for the treatment of depression. TMS Therapy® is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation which stimulates nerve cells in an area of the brain that is linked to depression, by delivering highly focused MRI-strength magnetic pulses. Patients being treated by NeuroStar TMS Therapy do not require anesthesia or sedation and remain awake and alert. It is a 40-minute, outpatient procedure that is prescribed by a psychiatrist and performed in a psychiatrist’s office. The treatment is typically administered daily for 4-6 weeks.
The engineering group from Sparton Medical Systems, Inc. provided project leadership, mechanical and electrical design, and coordination of outside development partners for the design of the electromechanical console. The console integrates software, precision mechanical components, and electronics into a system that drives Neuronetics’ core MRI-strength magnetic technology for therapeutic use.
“Sparton Medical has been a key development partner as Neuronetics has grown from a start-up to a full service medical device company,” observes Mark Riehl, VP Product Development and Operations at Neuronetics. “The contributions of the Sparton team have been essential to the successful design, implementation and manufacturing of our first product, the NeuroStar TMS Therapy® System.”
“We congratulate Neuronetics on winning this prestigious award,” said Cary Wood, president and CEO, Sparton Corp. “We’re proud to have been a partner in developing this important non-invasive medical device. The combination of Neuronetics’ dynamic core technology and Sparton’s engineering and manufacturing expertise is a great example of how teams can work together to produce exciting innovations that are beneficial in treating chronic illnesses.”
Source: Sparton Medical Systems